We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00325546
Recruitment Status : Completed
First Posted : May 15, 2006
Last Update Posted : April 7, 2009
Information provided by:

Brief Summary:

Primary : effect on weight loss and weight maintenance over 9 months when prescribed with a hypocaloric diet in obese patients.

Secondary : effect on HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist circumference - safety and tolerability

Condition or disease Intervention/treatment Phase
Obesity Drug: Rimonabant (SR141716) Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 643 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities
Study Start Date : April 2006
Actual Primary Completion Date : April 2007
Actual Study Completion Date : April 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Primary Outcome Measures :
  1. Absolute change in weight from baseline to month 9

Secondary Outcome Measures :
  1. HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist circumference(physical examination, vital signs, ECG, laboratory tests, adverse events).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body mass index (BMI)> 25 kg/m²

Exclusion Criteria:

  • Absence of stable weight (variation < 5 kg) within three months prior to screening visit),
  • Absence of effective contraceptive method for females of childbearing potential,
  • Presence of treated or untreated type 1 or type 2 diabetes,
  • Systolic blood pressure > 165 mm Hg and/or diastolic blood pressure > 105 mm Hg on 2 consecutive visits from the screening to the inclusion visit,
  • Presence of secondary hypertension,
  • Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint (presence of any clinically significant endocrine disease according to the Investigator, obesity of known endocrine origin...)
  • Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study,
  • Presence of any clinically significant abnormality according to the Investigator on the ECG performed on the inclusion visit.
  • Presence or history of cancer within the past five years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer.
  • Related to previous or concomitant medications :

    • Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).
    • Antidiabetic drugs.
  • Related to laboratory findings:

    • Positive test for hepatitis B surface antigen and/or hepatitis C antibody.
    • Abnormal TSH level (TSH > ULN or < LLN).
    • Positive urine pregnancy test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00325546

Layout table for location information
Shangai, China, 200040
Korea, Republic of
Seoul, Korea, Republic of, 135-755
Taipei, Taiwan, 105
Sponsors and Collaborators
Layout table for investigator information
Study Director: ICD CSD Sanofi
Layout table for additonal information
Responsible Party: ICD Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00325546    
Other Study ID Numbers: EFC6001
First Posted: May 15, 2006    Key Record Dates
Last Update Posted: April 7, 2009
Last Verified: April 2009
Keywords provided by Sanofi:
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Body Weight
Anti-Obesity Agents
Cannabinoid Receptor Antagonists
Cannabinoid Receptor Modulators
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs